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Abstract
Introduction: The nicotinic α5 receptor subunit, encoded by CHRNA5, harbors multiple functional single nucleotide
polymorphisms (SNPs) that affect mRNA expression and alter the encoded protein. These polymorphisms are most
notably associated with drug-taking behaviors and cognition. We previously identified common SNPs in a distant
regulatory element (DRE) that increase CHRNA5 mRNA expression in the human prefrontal cortex (PFC) and confer
risk for nicotine dependence. Genome-wide epigenetic studies in PFC and adipose tissue find strong effects of the
DRE SNPs on CpG methylation. However, it is unclear whether DRE SNPs influence CpG methylation en route to
modulating CHRNA5 mRNA expression. It is also unclear whether these polymorphisms affect expression in other
brain regions, especially those mediating drug-taking behaviors.
Results: By measuring total and allelic CHRNA5 mRNA expression in human habenula and putamen autopsy tissues,
we found that CHRNA5 DRE variants considerably increase mRNA expression by up to 3.5-fold in both brain regions.
Our epigenetic analysis finds no association between CpG methylation and CHRNA5 mRNA expression in the PFC or
adipose tissues.
Conclusions: These finding suggests the mechanisms responsible for the genetic modulation of CpG methylation
and mRNA expression are independent despite the DRE SNPs being highly associated with both measures. Our
findings support a strong association between the DRE SNPs and mRNA expression or CpG methylation in the
brain and periphery, but the independence of the two measures leads us to conclude that environmental factors
affecting CpG methylation do not appear to directly modulate gene expression.
Keywords: Nicotinic receptors, Nicotine, mRNA expression, Enhancer, Repressor, Silencer, Methylation, Epigenetics,
Expression quantitative trait loci, eQTL, Functional polymorphism, Allelic expression
Introduction
Previous studies found that allelic variation in the
α5/α3/β4 neuronal nicotinic acetylcholine receptor
(nAChR) subunit gene cluster on chromosome region
15q25.1 significantly increases risk for addiction to mul-
tiple classes of drugs [1–9], but confers a protective effect
for cocaine addiction [8, 10]. This region also confers risk
for lung cancer and chronic obstructive pulmonary disease
(COPD) [2, 11–13]. A non-synonymous single nucleotide
polymorphism (SNP), rs16969968, in the gene encoding
the α5 subunit (CHRNA5) is most commonly implicated
in this gene cluster. Functional analysis of this SNP sug-
gests it reduces ligand-mediated signaling [14, 15]. In
addition to rs16969968 affecting protein function, SNPs in
a cis-acting distal regulatory element (DRE), located ~15
kb upstream of CHRNA5, increase mRNA expression in
the prefrontal cortex (PFC) up to 4-fold [9]. This DRE har-
bors a cluster of six SNPs (rs7164030, rs1979905,
rs1979906, rs1979907, rs880395, and rs905740) in near
complete linkage disequilibrium (LD). Joint analysis of
rs880395 in the DRE with rs16969968 in the Collaborative
Genetic Study of Nicotine Dependence (COGEND) finds
increased risk for nicotine dependence compared to risk
associated with either SNP alone [9], suggesting that both
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SNPs can influence phenotypes associated with this gen-
omic region.
Knockout mouse studies examining the behavioral ef-
fects of habenular and ventral tegmental area (VTA)
Chrna5 mRNA expression find that mice with a null
mutation for Chrna5 significantly increase nicotine in-
take [15, 16] and exhibit attenuated nicotine-induced
locomotion [17]. Re-expressing Chrna5 in the medial
habenula (MHb) reduces nicotine consumption to wild-
type levels [16], suggesting that α5 nAChR mRNA ex-
pression in the MHb mediates negative reward signaling
through the habenulo-interpenduncular pathway. Ex-
pression of the α5 receptor subunit in GABAergic neu-
rons of the interpeduncular nucleus (IPN) was found to
further modulate this MHb output to serotonergic brain
regions [18]. The medial and lateral habenula are also
connected to brain regions classically associated with
drug-taking behaviors that express CHRNA5 mRNA.
This includes afferent connections from the nucleus
accumbens and efferent connections to the VTA and
substantia nigra, which go on to innervate the PFC and
striatum, respectively [19]. In the VTA, Chrna5 modulates
the sensitivity of dopaminergic neurons to acute nicotine
[15] but not ethanol administration [20]. Furthermore,
rs16969968 interacts with a splicing SNP in the dopamine
D2 receptor gene (DRD2), also implicated in addiction
[21], to affect multiple aspects of prefrontal cortex physi-
ology and behavior [22]. Together, these results demon-
strate a pervasive functional profile for CHRNA5 in brain
regions central to addiction and cognition. Despite strong
evidence for altered Chrna5 expression in the rodent
habenula affecting addiction phenotypes, and the associ-
ation of regulatory DRE SNPs with nicotine addiction, it is
unknown whether the DRE SNPs affect CHRNA5 mRNA
expression in the human habenula. However, evidence
that they modulate expression in the PFC, amygdala, and
nucleus accumbens [5, 6, 9, 23], suggests the DRE exerts
influence in cortical and subcortical brain regions.
CpG methylation in the CHRNA5 locus is strongly
influenced by the DRE polymorphisms according to
genome-wide scans of cis-methylation quantitative trait
loci (cis-mQTLs) in the prefrontal cortex [24] and biop-
sied adipose [25] tissue. Moreover, specific CpG sites
within the CHRNA5 promoter are hypermethylated in re-
sponse to adverse childhood events [26]. These same ad-
verse events confer risk for nicotine dependence, even
exhibiting an genotype x environment interaction specific-
ally for rs16969968 [27]. While it is reasonably hypothe-
sized that environmental factors affect methylation, which
then influences expression, this relationship has not been
formally tested. Thus, the relationship between genotype,
methylation, and expression remains unclear and needs to
be resolved in order to identify the mechanisms under-
lying substance abuse with respect to CHRNA5.
Here, we have tested the influence of the DRE vari-
ants modulate on CHRNA5 mRNA expression in the
human habenula and putamen, by measuring total and
allelic CHRNA5 mRNA expression. We also compared
expression and CpG methylation across DRE geno-
types using publicly available genome-wide datasets
from BrainCloud [28], BrainCloudMethyl [24], and the
Multiple Tissue Human Expression Resource [25, 29].
We find the DRE SNPs modulate expression in the pu-
tamen and habenula. However, in PFC and adipose tis-
sues where we have measures of both expression and
methylation from the same individuals, we find that




Twenty-one human habenula autopsy samples were dis-
sected by a trained neuropathologist (CRH) or obtained
from the NICHD Brain and Tissue Bank for Developmen-
tal Disorders, while 57 human posterior putamen autopsy
samples were obtained through the University of Miami
Brain Endowment Bank. Demographics for these human
tissues are presented in Table 1. Post-mortem tissue collec-
tion was performed in accordance with local Institutional
Review Board approvals. The overall study described here
was performed in accordance with the Institutional Review
Board of The Ohio State University.
Nucleic acid isolation & complementary DNA (cDNA)
synthesis
Genomic DNA (gDNA) was isolated from all human tis-
sues using a ‘salting out’ method adjusted for lipid-rich
brain tissue, as previously described [9]. Total RNA was
isolated by homogenizing the tissues in TRIzol and
precipitating the RNA from the aqueous phase using iso-
propanol. We further purified the RNA using RNeasy Mini
Kit spin columns (Qiagen, Germantown, MD) and digested
latent gDNA on the column with recombinant DNaseI, as
previously described [9]. cDNA preparations were made
using 0.5 μg total RNA for each sample. Gene-specific
primers (25 nM) supplemented with Oligo-dT (5 μM) were
used to prime the reverse transcription reaction.
Sample genotyping
SNPs rs16969968, rs615470, and rs7164030 were geno-
typed by restriction fragment length polymorphism
(RFLP) methods. rs16969968 and rs615470 serve as
marker SNPs for measuring allelic mRNA expression,
which were chosen because of their high minor allele
frequencies, high likelihood to be present in the mature
mRNA, and LD pattern which suggests their minor
alleles are present on different haplotypes. rs7164030
serves as the representative marker of DRE, which
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include 5 additional SNPs in high LD (rs1979907, rs19
79906, rs1979905, rs880395, and rs905740). The gDNA
regions surrounding these SNPs were amplified using
primers tagged with a fluorophore (6-FAM or HEX) and
the resultant amplicons were cut with restriction enzymes
(rs16969968-Taq1a; rs615470-CviQI; rs7164030-Tsp509I)
that recognize only one of the two alleles resulting from the
presence of the polymorphism. Fragments were resolved
on an ABI 3730 DNA Analyzer (Life Technologies) or by
standard gel electrophoresis (1.5 % agarose).
Total and allelic mRNA expression measurement
Total CHRNA5 and β-actin (ACTB) mRNA expression
was measured in all human and mouse tissues by qPCR
using an ABI 7500 Fast Sequence Detection System (Life
Technologies). In addition, we measured the expression
of two highly-enriched habenula markers, POU4F1 and
CHRNB3, in the habenula samples to determine the pur-
ity of the dissections. The relative quantity of CHRNA5
mRNA was normalized within each sample to ACTB
mRNA expression for statistical analysis. The influences
of available covariates (age, sex, race, post-mortem inter-
val, RNA integrity number, nicotine use, or habenula
purity) were tested on ACTB-normalized total CHRNA5
mRNA expression in each brain region using stepwise
linear regression.
We quantified allelic mRNA expression in habenula
and putamen samples heterozygous for rs16969968 or
rs615470 using a fluorescent primer extension method
(SNaPshot), as previously described [9]. Fluorescently-
labeled primer extension fragments, representing the
two different alleles of rs16969968 or rs615470, were re-
solved on an ABI 3730. The fluorescent peak heights for
each allele, determined using GeneMapper 4.0 Software
(Life Technologies), were used to calculate relative allelic
expression ratios (ancestral/variant allele). For each sam-
ple, at least two separate measurements were used to
calculate allelic expression imbalance (AEI). Allelic ratios
for cDNA were normalized against the overall average
ratio calculated for gDNA for each marker SNP. We
subsequently compared the absolute magnitude of the
allelic expression in samples heterozygous for rs7164030
versus homozygotes for either allele.
CHRNA5 mRNA expression and CpG methylation using
BrainCloud and MuTHER
We utilized existing repositories of transcriptome-wide
mRNA expression, genome-wide methylation profiles, and
SNP genotypes in postnatal PFC (BrainCloud; http://brain
cloud.jhmi.edu/) and adipose tissue (MuTHER; http://www
.muther.ac.uk/) to test interactions between DRE SNPs,
expression, and CpG methylation. Detailed methods for
these studies are available in their primary publications
[24, 25, 28, 29]. Source data can be obtained from the
Gene Expression Omnibus (Accession: GSE30272), dbGAP
(Accession: phs000417), EMBL-EBI ArrayExpress (Acces-
sions: E-TABM-1140 and E-MTAB-1866), and by applying
to the TwinsUK Consortium (http://www.twinsuk.ac.uk/).
Briefly, samples were genotyped with a variety of Illu-
mina arrays (HumanHap300, HumanHap610Q, Human
Hap650Y, Human 1 M-Duo, and Human 1.2 MDuo 1 M)
and imputed to 1000 Genomes populations using IM-
PUTE2. From the imputed data, we used rs7164030 as a
surrogate marker of the DRE to test genetic effects on
expression and methylation. Samples were also measured
for genome-wide CpG methylation, using the Infinium
HumanMethylation450k BeadChip assay, and
transcriptome-wide mRNA expression, using Illumina 49
K Oligo Arrays (BrainCloud) or HumanHT-12 v3 Bead-
Chips (MuTHER). For analyses, we used CpG probes
cg22563815 and cg17108064, which measures methylation
at CpG sites 913 and 802 nucleotides upstream of the an-
notated CHRNA5 gene (hg19 chr15: 78856949 and
chr15:78857060), respectively. Although these CpG probes
are ~12 kb downstream from the DRE SNPs, they are
among the highest scoring mQTLs for the DRE SNPs in
the CHRNA5 gene region. For expression, we used probes
hHC002196 (BrainCloud) and ILMN_1770044 (MuTHER),
which hybridize to CHRNA5 mRNA in the 3′ untranslated
region and exon 5, respectively.
Table 1 Demographic characteristics for habenula and posterior putamen tissues
Tissue (n) Sex Racea Nicotine use Cocaine use Age (Avg. ± S.D.) PMI (Avg. ± S.D.) RIN (Avg. ± S.D.
Habenula (21) Male: 12 EA: 19 Users: 5 Users: N/A 57.5 ± 18.6 35.6 ± 38.0 5.2 ± 1.4
Female: 9 AA: 2 Non-users: 7 Non-users: N/A
Unknown: 9
Putamen (55) Male: 46 EA: 34 Users: 24 Users: 22 35.6 ± 8.9 16.7 ± 5.4 N/A
Female: 9 AA: 10 Non-users: 31 Non-users: 33
Other: 11
aEA: European-American, AA: African-American, Other: Mixed race and/or Hispanic
Abbreviations: PMI post-mortem interval, RIN RNA Integrity Number, as measured by Agilent Bioanalyzer 2100, N/A data not available
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Statistical analyses
Statistical analyses were performed in R (x64 v.3.1.0) with
standardized β-coefficients calculated by the QuantPsyc
package. For all datasets, we used interquartile range
(IQR) to exclude extreme outliers, defined as data points
below Q1  3xIQR or above Q3þ 3xIQR. Next, we iden-
tified significant covariates using stepwise linear regression
and AIC, using the [step] function to reach a minimal
adequate model. We subsequently included significant
covariates in analyses of rs7164030 genotype on expres-
sion and methylation or as interaction terms in linear
regression models of expression and methylation. Poten-
tial covariates in our putamen and habenula expression
datasets included age, sex, race, smoking history, cocaine
use, and post-mortem interval. Potential covariates in the
BrainCloud data included sex, age, race, and an estimate
of neuron enrichment that was specific to methylation
data [30]. Age and batch-specific effects were considered
as a potential covariate in the MuTHER dataset. We
tested for an overall effect of methylation on expres-
sion using linear regression across the entire Brain-
Cloud or MuTHER sample populations and report the
standardized β-coefficient for the methylation measure.
We further tested this relationship within each rs7164030
genotype group to identify any genotype-specific effect
that could be obscured when examining the population as
a whole.
Results
Total and allelic CHRNA5 mRNA expression in putamen
and habenula
Two putamen samples were excluded from analyses due
to poor RNA quality as indicated by ACTB expression
>2 standard deviations above the mean of the remaining
samples, leaving 55 total putamen samples. Stepwise lin-
ear regression revealed sex as a significant covariate of
CHRNA5 mRNA expression measured via qPCR in the
putamen. We found a significant effect of the represen-
tative DRE SNP rs7164030 genotype on putamen ex-
pression (n=55, F=28.90, p=1.82×10−6; Fig. 1), whereby
homozygous minor “G” allele samples expressed 3.5-fold
more CHRNA5 mRNA than homozygous major “A”
allele samples, consistent with our previous findings in
PFC [9]. Examining the influence of rs7164030 on habe-
nular CHRNA5 mRNA expression via qPCR with race as
a significant covariate revealed no significant effect of
genotype, although the direction of the genotypic effect
is consistent with our findings in the putamen and PFC.
We also noted that the purity of the habenula dissection,
as determined by POU4F1 or CHRNB3 expression, did
not influence CHRNA5 mRNA expression. A comparative
analysis of habenula CHRNA5 mRNA expression with
previously measured PFC expression found no enrichment
in the habenula relative to the PFC in humans, consistent
with previous reports of generally low expression in these
areas in rodents [18, 31].
We measured allelic mRNA expression in 21 of 55 pu-
tamen samples heterozygous for either rs16969968 or
rs615470 (9 co-heterozygous) and 9 of 21 habenula sam-
ples heterozygous for rs16969968. The low expression of
CHRNA5 in both tissues required us to average the allelic
ratio measurements at the two marker SNPs, as done for
the putamen, or take an increased number of measure-
ments at the same SNP, as done for the habenula. Thus,
the averaged data is only presented for the 9 co-
heterozygous putamen samples, while the data for all
habenula samples is presented for marker SNP
rs16969968. Samples heterozygous for rs7164030 exhib-
ited AEI ranging from 2.1 to 6.5-fold differences between
the expression of the two alleles, while samples homozy-
gous for either allele of rs7164030 all displayed AEI of <2-
fold, consistent across both brain regions. We observed
greater expression for the major allele of rs16969968 rela-
tive to the minor allele in all but one sample exhibiting
>2-fold AEI, consistent with the major allele for
rs16969968 residing on the high expressing DRE haplo-
type. Comparing the absolute magnitude of AEI across
rs7164030 genotype, we find heterozygotes exhibit signifi-
cantly greater AEI versus homozygotes (F=7.99, p=0.012;
Fig. 2), supporting the hypothesis that the DRE SNPs exert
their function in both the habenula and putamen.
DRE SNPs, CHRNA5 expression, and methylation in
BrainCloud and MuTHER
CHRNA5 mRNA expression differed significantly across
rs7164030 genotype in the BrainCloud dataset (F=28.57,
Fig. 1 CHRNA5 mRNA expression in the putamen compared across
rs7164030 genotypes, as measured by qPCR. Samples homozygous
for the major “A” allele (A/A) of rs7164030 have approximately
3.5-fold less CHRNA5 mRNA versus samples homozygous for the
minor “G” allele, with heterozygotes exhibiting intermediate levels
(ANOVA p=1.82×10−6)
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p=2.30×10−7; age and sex included as significant co-
variates). Consistent with our previous study in the PFC
[9], samples homozygous for the variant G allele of
rs7164030 expressed 3.67-fold more CHRNA5 mRNA
than samples homozygous for the ancestral A allele
(Fig. 3a). rs7164030 genotype was also significantly asso-
ciated with CHRNA5 expression in MuTHER (F=13.06,
p=3.28×10−4; Fig. 3b).
Methylation in the BrainCloud dataset significantly
differed across rs7164030 genotype in the PFC for both
CpG probes (cg22563815: F=109.17, p=5.87×10−21; race,
age, and neuron enrichment estimate as significant co-
variates; cg17108064: F=191.06, p=1.77×10−31; race as a
significant covariate). Here, samples homozygous for the
variant G allele of rs7164030 had significantly greater
CpG methylation at both probes relative to the ancestral
A allele homozygotes (Fig. 3c and e). Methylation was also
significantly higher across both probes for the variant G
allele carriers in the MuTHER dataset (cg22563815: F =
1703.48, p=5.54×10−172; bisulfite conversion gDNA concen-
tration and efficiency included as covariates; cg17108064:
F=614.33, p=3.73×10−92; batch and bisulfite conversion effi-
ciency included as covariates; Fig. 3d and f).
Because the DRE SNPs are associated with significant
increases in both expression and methylation, we further
asked if the increased expression can be predicted by
greater methylation using linear regression. In both the
BrainCloud and MuTHER datasets, we found that
methylation at either probe did not significantly predict
CHRNA5 expression. The linear model for cg22563815
in BrainCloud (Expression ~ sex + cg22563815*methy-
lation*race*age*neuron count estimate*rs7164030) found
no significant effect for methylation at cg22563815 (t =
0.42, p=0.67 β=0.30; Fig. 4a). Similarly, the model for
cg17108064 (Expression ~ sex + age + cg17108064*
race*rs7164030) also revealed no significant effect for
methylation (t=−0.84, p=0.40 β=−0.11; Fig. 4b). In the
MuTHER dataset, the linear model for methylation at
cg22563815 (Expression ~ cg22563815*bisulfite conversion
concentration*bisulfite conversion efficiency*rs7164030)
showed a trend towards significance (t=−1.95, p=0.051, β=
−2.34; Fig. 4c), while methylation at cg17108064 (Expres-
sion ~ cg17108064*batch*bisulfite conversion efficiency*
rs7164030) did not predict expression (t=1.48, p=0.14,
β=0.99; Fig. 4d).
Evident in each of our linear models is the confound-
ing influence of genotype on both methylation and ex-
pression (Fig. 4). Although we accounted for this
influence statistically in the model examining all sam-
ples, we subsequently tested whether it was still possible
for methylation to influence expression on specific gen-
etic backgrounds (i.e. if one were to carry the DRE
SNPs), which could be obscured in the full linear model.
Thus, we performed linear regression within each of the
rs7164030 genotype groups, finding no evidence that
methylation at either probe affects expression in any of
the genetic backgrounds defined by the DRE SNPs
(Table 2).
Discussion
Our findings reveal pervasive influence of the DRE SNPs
on CHRNA5 mRNA expression and methylation in brain
and adipose tissue, whereby the minor DRE alleles are
associated with greater expression and methylation. This
genotypic difference is consistent with our findings in
the PFC for both the BrainCloud dataset and in our pre-
vious study [9]. The habenula did not show a main effect
of the DRE SNPs on total CHRNA5 expression, but we
observed strong allelic differences in the habenula that
perfectly correlate with the DRE SNPs, consistent with
the interpretation that they modulate CHRNA5 expres-
sion in the habenula. While significant, the influence of
the DRE SNPs on CHRNA5 expression is not as strong
in adipose tissue. We previously reported no influence
of the DRE SNPs in lymphoblastoid cell lines (LCLs),
but other studies with larger sample sizes have found
cis-eQTLs for CHRNA5, implicating the DRE SNPs in
peripheral whole blood [32], monocytes [33], and lung
[34]. Thus, it is likely that the DRE SNPs are modulating
Fig. 2 Absolute allelic expression imbalance in putamen (filled
markers) and habenula (open markers) compared across rs7164030
genotype. Samples heterozygous for rs7164030 exhibit significantly
greater AEI than samples homozygous for rs7164030 (ANOVA
p=0.012), consistent with the expectation that AEI is observed in
samples heterozygous for the functional allele. Samples homozygous
for either DRE allele are not expected to exhibit AEI
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expression of CHRNA5 in peripheral tissues, but exert
less influence relative to their impact in the brain.
The location and epigenetic histone markings in the
CHRNA5 locus harboring the DRE SNPs previously led
us to propose they act in an enhancer [9]. Data from the
ENCyclopedia Of DNa Elements (ENCODE) Project
[35] viewed on the UCSC Genome Browser [36] shows
histone modifications in a lymphocyte cell line (GM12878)
consistent with enhancers, including histone 3 lysine 4
monomethylation (H3K4Me1) and light trimethylation
(H3K4Me3), and H3 lysine 27 acetylation (H3K27Ac).
However, when a portion of the DRE containing rs880395,
rs905740, and rs7164030 was sub-cloned into a vector up-
stream of a minimal promoter, it acted as a repressor, with
Fig. 3 Expression and methylation across rs7164030 genotype in BrainCloud and MuTHER. The major “A” allele of rs7164030 was significantly and
consistently associated with lower CHRNA5 mRNA expression in the BrainCloud (a) and MuTHER (b) datasets. The “A” allele was also associated
with lower CpG methylation measured at two different probes (cg22563815 and cg17108064) in the BrainCloud prefrontal cortex (c and e) and
the MuTHER adipose tissue (d and f)
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no significant expression differences between DRE haplo-
types [23]. Given these contradictory results, we find it
possible that the DRE contains both enhancer and repres-
sor elements. A dual enhancer/repressor mechanism is not
novel. Perhaps the most well-known example is the RE-1
Silencing Transcription Factor (REST), which silences
neuronal genes in the periphery [37], but has the ability to
enhance gene expression in the brain [38, 39]. Evolutionary
studies of cis-acting enhancer elements supports the possi-
bility that multiple variants affecting enhancer function can
arise together within a population to high frequency [40],
sometimes co-opting cryptic or existing regulatory sequen-
ces to derive their new functions [41], as we would assume
occurred for the DRE SNPs in CHRNA5. A more thorough
analysis of the evolutionary constraints on the CHRNA5
locus could provide clues about the adaptive evolution of
regulatory elements in humans.
In addition to the epigenetic histone modifications
present in the CHRNA5 locus, CpG methylation is strongly
associated with CHRNA5 SNPs. Since CpG methylation
can repress transcription [42] it led us to examine CHRNA5
CpG methylation and mRNA expression using BrainCloud
Fig. 4 Scatterplots for CpG methylation and CHRNA5 mRNA expression in BrainCloud and MuTHER. CHRNA5 expression is moderately correlated
with CpG methylation measured in the BrainCloud prefrontal cortex data by probes cg22563815 (a) and cg17108064 (b). Similar results were
obtained for the same probes in the MuTHER adipose tissue (c and d). However, the correlation between expression and CpG methylation is
explained by rs7164030 genotype, apparent by the stratification of the genotype groups in the scatterplots (A/A = red circles, A/G = blue
squares, G/G = black diamonds). Furthermore, linear regression performed within each genotype group finds no significant relationship between
methylation and expression, arguing against direct modulation of expression by methylation
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and MuTHER. Because the DRE SNPs were strongly asso-
ciated with increased methylation and expression in both
datasets, we expected methylation to be positively corre-
lated with expression, thus providing mechanistic evidence
linking epigenetic modulation of the CHRNA5 locus and
gene expression. Instead, we found that methylation and
expression were independent when accounting for DRE
genotype and other significant covariates. Evidence that
CHRNA5 expression and methylation are independent is
important for delineating mechanisms underlying drug ad-
diction that is associated with this gene locus, since both
methylation and expression apparently influence addiction
risk. One explanation that unifies expression and methyla-
tion, that also serves as a caveat of this study, is that methy-
lation influences the expression of CHRNA5 in a way that
was not detected here. Such scenarios could include
changes in alternative splicing or transcription start site
usage which do not change the overall levels of CHRNA5
mRNA, but alter the makeup of the mRNA. The GEN-
CODE project has annotated an alternatively spliced tran-
script (ENST00000559554.1), but it has only been observed
as an expressed sequence tag in a neuroblastoma cell line.
Methylation at the CHRNA5 locus is sensitive to envir-
onmental factors, as demonstrated by childhood adverse
events (CA). CA results in hypermethylation and in-
creased risk for drug dependence [26, 27]. Males carry-
ing rs16969968 who experience CA are at greater risk
for dependence relative to those without rs16969968
[27]. In the context of our findings, we do not find it
likely that hypermethylation changes mRNA expression,
although we cannot rule out that CA-induced hyperme-
thylation can be much greater than observed in our
samples and subsequently affect expression. Reanalyzing
existing CA studies to include the DRE SNPs in addition
to rs16969968 could shed some light on the relation-
ships between CA, methylation, and smoking risk. How-
ever, a study examining environmental factors, CpG
methylation, mRNA expression, and drug dependence
would be ideal for resolving the risk conferred by
15q25.1.
Finally, the strong impact of Chrna5 expression in
mouse MHb and VTA on nicotine consumption despite
low levels of mRNA expression in mice and humans sig-
nifies the importance of the specific cell types on which
these receptors are expressed. The MHb afferents that
express the α5 subunit project to the interpeduncular
nucleus [19], which also contains GABAergic neurons
expressing the α5 subunit [18], modulating aversiveness
associated with nicotine intake [16] and withdrawal [43].
Dopaminergic neurons in the VTA express the α5 recep-
tor subunit [44] and project to multiple addiction-
related brain regions, including the cortex and insula via
the mesocortical pathway and limbic areas, the nucleus
accumbens, lateral habenula, and amygdala through the
mesolimbic pathway [45]. Finding ways to modulate the
firing of the cells expressing CHRNA5, directly or indir-
ectly, without targeting nicotinic α5-containing receptors
could provide avenues for treating addictive behaviors
that circumvent the inherent challenges of developing
small molecules for nicotinic receptors. Identifying prom-
ising new targets will require a firm understanding of ad-
diction neurocircuitry and of genetic expression within
specific cell types in the habenula, IPN, and VTA, in order
to exploit the aversive signaling properties of these cells in
the context of drug abuse.
Conclusions
Our findings support pervasive but independent influ-
ence of the CHRNA5 DRE SNPs on mRNA expression
and CpG methylation in the brain and periphery. With
evidence that environmental influences modulate CpG
methylation in this region, we advocate for future studies
to incorporate environmental, epigenetic, and genetic
factors in the pathogenesis of addiction associated with
Table 2 Linear regression results for CpG methylation and CHRNA5 gene expression across rs7164030 genotypes
Dataset CpG probe rs7164030 genotype (n) Standardized β coefficient for methylation t-value p-value
BrainCloud cg22563815 A/A (118) 0.267 0.363 0.717
cg22563815 A/G (77) 1.166 0.390 0.698
cg22563815 G/G (25) −16.837 −0.397 0.700
cg17108064 A/A (118) −0.171 −1.424 0.157
cg17108064 A/G (77) 0.153 1.072 0.288
cg17108064 G/G (25) 0.024 −0.040 0.969
MuTHER cg22563815 A/A (184) 4.069 0.528 0.598
cg22563815 A/G (270) 0.010 0.014 0.989
cg22563815 G/G (111) −2.964 −1.718 0.089
cg17108064 A/A (184) 0.981 0.398 0.691
cg17108064 A/G (270) −1.288 −0.813 0.417
cg17108064 G/G (111) −2.510 −0.639 0.524
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CHRNA5. Finally, clinical and molecular genetic studies
of the CHRNA5/A3/B4 locus suggest the presence of un-
accounted for functional regulatory variants [46], requir-
ing additional studies to delineate the exact functional
variant(s) and their phenotypic impact to further disen-
tangle disease risk conferred by 15q25.1.
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